A-LIGN Issues CMMC Level 2 Certification to Quiet Professionals
TAMPA, Fla., May 29, 2025 /PRNewswire/ -- A-LIGN, a leading Cybersecurity Maturity Model Certification (CMMC) Third-Party Assessor Organization (C3PAO), proudly announces the issuance of one of its first CMMC Level 2 certifications to Quiet Professionals LLC. This milestone underscores A-LIGN's dedication to helping U.S. Department of Defense (DoD) contractors meet stringent cybersecurity requirements while safeguarding sensitive Controlled Unclassified Information (CUI).
The CMMC program requires all DoD defense contractors under Level 2 to meet cybersecurity controls and be certified by a C3PAO assessment. Prime contractors and their subcontractors are required to demonstrate that cybersecurity controls have been sufficiently implemented through the completion of independent validation activities performed by an authorized C3PAO like A-LIGN.
'At A-LIGN, we are at the forefront of CMMC, providing businesses with expert guidance to navigate the new DoD standards with confidence,' said Jennifer Hawks, Federal Practice Lead at A-LIGN. 'As a trusted C3PAO, A-LIGN leverages its team of expert CCAs and CCPs to guide organizations through the complex process of CMMC Level 2 certification. We are honored to work with industry leaders like Quiet Professionals, one of the first organizations to secure certification, as they set the standard for cybersecurity excellence.'
Quiet Professionals is a veteran-founded company providing secure, scalable solutions for national security and defense organizations, headquartered in Tampa. As the company advances solutions in OSINT, Geospatial Analytics, and Cloud Computing, earning CMMC Level 2 certification reinforces the company's ability to securely support customers' critical missions.
'Our team committed to fully understanding NIST 800-171 and each control family. We developed tailored solutions to meet every requirement, drawing from industry research and leveraging our Microsoft partnership. A-LIGN was a strong partner throughout the process to achieve CMMC Level 2 certification. Their structured approach and expertise helped validate the work our cybersecurity team has done. This achievement is a testament to our collective effort,' said Cory Wilson, Director of Information Technology at Quiet Professionals.
As a top C3PAO with over 20 years of experience, A-LIGN has completed over 1,000 NIST-based assessments, including FedRAMP, GovRAMP, NIST 800-171. Contact A-LIGN today to secure your spot in the CMMC certification queue and streamline compliance with an expert-driven approach.
About A-LIGN
A-LIGN is the leading provider of high-quality, efficient cybersecurity compliance programs. Combining experienced auditors and audit management technology, A-LIGN provides the widest breadth and depth of services including SOC 2, ISO 27001, HITRUST, FedRAMP, and PCI. A-LIGN is the number one issuer of SOC 2 and HITRUST and a top three FedRAMP assessor. For more information, visit a-lign.com.
About Quiet Professionals LLC
Quiet Professionals LLC is a veteran-founded defense and technology company specializing in intelligence, advanced analytics, cybersecurity, and mission support for U.S. government agencies. With roots in the Special Operations Forces (SOF), Quiet Professionals provides highly specialized expertise in counter-threat intelligence, geospatial analysis, cloud integration, and secure technology and operational support to address today's most complex national security challenges with precision and speed.
Headquartered in Tampa, Florida, near MacDill Air Force Base—home to U.S. Special Operations Command (USSOCOM) and U.S. Central Command (USCENTCOM)—Quiet Professionals partners with industry leaders like Esri, Microsoft Azure, and Databricks to deliver mission-critical solutions. Built on a foundation of service and excellence, Quiet Professionals empowers defense and intelligence agencies with the expertise, technology, and operational agility to outpace emerging threats and safeguard national security. For more information, visit quietprofessionalsllc.com.
Media Contact:
Elizabeth Strickert
[email protected]
View original content to download multimedia: https://www.prnewswire.com/news-releases/a-lign-issues-cmmc-level-2-certification-to-quiet-professionals-302467406.html
SOURCE A-LIGN
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
40 minutes ago
- Yahoo
'50s-themed San Angelo burger restaurant shuts down
SAN ANGELO, Texas (Concho Valley Homepage) — Grill-A-Burger, a San Angelo-based, '50s-themed diner specializing in burgers, was shut down in April after years of operation, the restaurant's owner has confirmed. Katherine Martinez, the owner of Grill-A-Burger and a San Angelo realtor, stated that the restaurant officially closed at the end of April. She said multiple reasons guided her decision to shut the business down. 'It was a hard choice, but it was a personal choice,' Martinez said. Chief among her reasons for closing Grill-A-Burger is her family. She said Grill-A-Burger began with her three teenage boys and niece, but has dwindled to just her over the years as her sons grew up, started families of their own and moved out of San Angelo. 'Me being a realtor and trying to run a restaurant, it was a lot,' Martinez said. 'At this point, I had to do what's right for my family and for myself.' Personal health concerns also played a role in the closure. Martinez shared that she is facing her own health problems as her mother faces the aftermath of pancreatic cancer, issues that led her to reevaluate how she spends her time. English Newsom Cellars to hold grand opening for San Angelo tasting room 'When you own a restaurant, you're basically married to it, and it became very, very difficult for me to leave town in order to take care of my family priorities that I needed to take care of,' Martinez said. 'It put a lot of stress on me.' Martinez also cited rising food costs spurred by inflation as another driving factor behind the closure. 'Inflation in general, I think, has really hurt a lot of small businesses,' Martinez said. Grill-A-Burger opened at 1025 N. Chadbourne St., the former home of Charcoal House, in November 2016. A second location was opened at 2833 Southland Blvd. in 2020 but was shut down amid a decline in business caused by the COVID-19 pandemic. Martinez encouraged San Angelo residents to support local businesses by shopping and eating locally. She thanked those who have visited Grill-A-Burger over the years and provided her with fond memories. 'I just thank the community for their support,' Martinez said. 'We were open for almost 10 years, and that says a lot in the industry.' With Grill-A-Burger now closed, the property the restaurant operated from is now for sale. Martinez encouraged those interested in purchasing the property to contact her at (325)-277-5636. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
an hour ago
- Yahoo
Mets calling up Ronny Mauricio after hot minors start
Ronny Mauricio has made it back to the majors. The former top prospect is being promoted Tuesday and will join the team in Los Angeles for the second matchup of its four-game set with the Dodgers, The Post's Joel Sherman confirmed. Advertisement While the corresponding move is not yet known, Mark Vientos appeared to tweak his hamstring during the 10th inning of Monday's 4-3 win. Ronny Mauricio in 2023. JASON SZENES FOR THE NEW YORK POST Mauricio, 24, tore his ACL in 2023 months after making his debut and did not appear in a major-league or minor-league game. He appeared in 26 games for the Mets that year, hitting .248 with a .643 OPS while playing third base, second base and shortstop. Mauricio been hitting well in the minors this year, posting an .892 OPS and .323 average while spending time across all three levels. The infielder recently hit a massive homer with Triple-A Syracuse. Ronny Mauricio during spring training. Corey Sipkin for the NY POST 'He's doing a great job. No. 1 is health and getting him back and building up the volume. We're continuing to do that,' Met president of baseball operations David Stearns said last Friday. 'Any time you see players consistently hit lasers all over the field, which is what he's doing right now in Triple-A, you pay attention. We're paying attention and will continue to monitor that and see where it goes.' Advertisement The Mets wanted to give Mauricio plenty of time to get his feet back under him following the injury, but Stearns previously said those plans could be altered if the major-league roster needed help. CHECK OUT THE LATEST MLB STANDINGS AND METS STATS It's not yet known whether the Mets are demoting a player or making a move to replace Vientos, who grabbed his hamstring while attempting to run Monday night. Both Vientos and manager Carlos Mendoza indicated they did not know yet if he would have to be sidelined. 'There aren't specific, 'You need to check this box. You need to check that box,' ' Stearns said of Mauricio last week. 'I think it's more subjective. Is he comfortable playing the field regularly? Does he look right? Offensively, it sure does seem he got himself right pretty quickly, which is very impressive. He certainly has development left in his offensive game. He's likely never going to be the type of guy with Juan Soto-type plate discipline. But there are probably some strides he can make there.'
Yahoo
an hour ago
- Yahoo
Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia
SOUTH SAN FRANCISCO, Calif., June 03, 2025--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that its pivotal Phase 3 NEAT (Neurological Effects of eDSP on Subjects with A-T; NCT06193200/IEDAT-04-2022) clinical trial in the rare neurodegenerative disease Ataxia-Telangiectasia (A-T) has reached an important milestone as enrollment now exceeds 75% with a total of 65 participants randomized in the study's targeted 86 participants in the six to nine year-old primary analysis population. Key Phase 3 NEAT clinical trial enrollment highlights to date include: A total of 76 participants have been enrolled, including 65 participants in the six to nine year-old primary analysis population and 11 participants aged 10 years or older. Study powering based on currently enrolled participants is approximately 80%. The rate of screening and randomization activities has materially increased with the recent activation of all study sites. A total of 108 NEAT participants have been screened to date with a low screen failure rate of 10%. All 37 NEAT participants to date have elected to transition to the NEAT open label extension (OLE) study (NCT06664853/IEDAT-04-2022). Participants who complete the full treatment period, complete study assessments, and provide informed consent are eligible to transition to the OLE study. Assuming positive study results, the company plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the second half of 2026. Quince was granted FDA Fast Track designation for the company's eDSP System for the treatment of patients with A-T based on the potential for eDSP to address a high unmet medical need. NEAT is an international, multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the neurological effects of Quince's lead asset, eDSP (dexamethasone sodium phosphate [DSP] encapsulated in autologous red blood cells; previously referred to as EryDex) in patients with A-T. Participants are randomized (1:1) between eDSP or placebo and treatment consists of six infusions scheduled once every 21 to 30 days. The primary efficacy endpoint will be measured by the change from baseline to last efficacy visit in the rescored modified International Cooperative Ataxia Rating Scale (RmICARS) compared to placebo. About Ataxia-Telangiectasia A-T is an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in the ATM gene, which is responsible for cell homeostatic and cell division functions including but not limited to double-stranded DNA repair. Typically, A-T is first diagnosed before the age of five as children begin to develop an altered gait and fall with greater frequency. Neurological symptoms worsen and patients with A-T frequently become wheelchair-bound by adolescence. Teenage years for patients with A-T are typically marked by repeated infections, pulmonary impairment, and malignancies. The median lifespan is approximately 25 to 30 years old with mortality due to infections and malignancy. Based on IQVIA Medical Claims (Dx), PharmetricsPlus (P+), and IQVIA Analytics information, there are approximately 4,600 diagnosed patients with A-T in the U.S. Quince estimates that there are approximately 5,000 patients with A-T in the U.K. and EU4 countries. There are currently no approved therapeutic treatments in any global market for A-T. About eDSP for A-T eDSP is comprised of dexamethasone sodium phosphate (DSP) encapsulated in a patient's own red blood cells (autologous erythrocytes). DSP is a corticosteroid well known for its anti-inflammatory properties as well as its dose-limiting toxicity due to adrenal suppression. The eDSP System is designed to provide the efficacy of corticosteroids and to reduce or eliminate the significant adverse effects that accompany chronic use of corticosteroid treatment. eDSP leverages Quince's proprietary Autologous Intracellular Drug Encapsulation, or AIDE, technology platform, which is a novel drug/device combination that uses an automated process designed to encapsulate a drug into the patient's own red blood cells. Red blood cells have several characteristics that make them a potentially effective vehicle for drug delivery, including potentially better tolerability, enhanced tissue distribution, reduced immunogenicity, and prolongation of circulating half-life. Quince's AIDE technology is designed to harness these benefits to allow for the chronic administration of drugs that have limitations due to toxicity, poor biodistribution, suboptimal pharmacokinetics, or immune response. About Quince Therapeutics Quince Therapeutics, Inc. (Nasdaq: QNCX) is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. For more information on the company and its latest news, visit and follow Quince on social media platforms LinkedIn, Facebook, X, and YouTube. Forward-looking Statements Statements in this news release contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements contained in this news release may be identified by the use of words such as "believe," "may," "should," "expect," "anticipate," "plan," "believe," "estimated," "potential," "intend," "will," "can," "seek," or other similar words. Examples of forward-looking statements include, among others, statements relating to the timing, success, and reporting of results of the clinical trials and related data, including plans and the ability to enroll participants, impact of closing enrollment, conduct, and/or complete current and additional studies; current and future clinical development of eDSP, including for the potential treatment of Ataxia-Telangiectasia (A-T), Duchenne muscular dystrophy (DMD), and other potential indications; the strategic development path for eDSP; planned regulatory agency submissions, including NDAs, and clinical trials and timeline, prospects, and milestone expectations; and the potential benefits of eDSP and the company's market opportunity. Forward-looking statements are based on Quince's current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict and could cause actual results to differ materially from what the company expects. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties described in the section titled "Risk Factors" in the company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 13, 2025, and other reports as filed with the SEC. Forward-looking statements contained in this news release are made as of this date, and Quince undertakes no duty to update such information except as required under applicable law. View source version on Contacts Media & Investor Contact: Stacy RoughanQuince Therapeutics, President, Corporate Communications & Investor Relationsir@ Sign in to access your portfolio
